证券代码：688468 证券简称：科美诊断 公告编号：2026-001 科美诊断技术股份有限公司 2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （2）预计2025年度归属于母公司所有者的扣除非经常性损益后的净利润为人民币2,600万元到3,200万 元，与上年同期（法定披露数据）相比，同比减少68.23%至74.19%。 （一）业绩预告期间 （1）经财务部门初步测算，科美诊断技术股份有限公司（以下简称"公司"）预计2025年年度实现归属 于母公司所有者的净利润为人民币4,000万元到4,800万元，与上年同期（法定披露数据）相比，同比减 少62.23%至68.52%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 （一）公司2024年实现利润总额为13,791.88万元，归属于母公司所有者的净利润为12,707.47万元，归属 于母公司所有者的扣除非经常性损益后的净利润为10,073.02万元。 （二）2024年度基本每股收益为0.32元。 2025 ...

证券日报网讯 1月28日，科美诊断发布公告称，公司预计2025年年度实现归属于母公司所有者的净利润 为人民币4，000万元到4，800万元，与上年同期相比，同比减少62.23%至68.52%；预计归属于母公司 所有者的扣除非经常性损益后的净利润为人民币2，600万元到3，200万元，同比减少68.23%至 74.19%。 （文章来源：证券日报） ...

智通财经APP讯，科美诊断(688468.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润为4000万元到4800万元，与上年同期(法定披露数据)相比，同比减少62.23%至68.52%。 ...

Core Viewpoint - Company expects a significant decrease in net profit for 2025, projecting between RMB 40 million to 48 million, which represents a year-on-year decline of 62.23% to 68.52 due to industry pressures [1] Financial Performance - The anticipated decline in net profit is primarily attributed to the impact of centralized procurement in the in vitro diagnostic industry, leading to price pressures on the company's main products and a decrease in main business revenue [1] - The company reported a reduction in non-recurring gains such as government subsidies compared to the previous year [1] Strategic Initiatives - To enhance core competitiveness, the company maintains a high level of investment in product innovation [1] - The company adheres to a long-term operational philosophy of serving human health through leading technology and innovative products, leveraging its proprietary LiCA® technology platform [1] - The company is focused on a dual-driven strategy of import substitution and clinical interactive innovation to create high-cost performance clinical products [1] Future Outlook - The company plans to continue its innovation-driven development path, strengthen cost management, actively respond to industry changes, and steadily advance the construction of core competitiveness to achieve sustainable high-quality development [1]

证券代码：688468 证券简称：科美诊断 公告编号：2026-001 （三）本次业绩预告未经注册会计师审计。 科美诊断技术股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况 （1）经财务部门初步测算，科美诊断技术股份有限公司（以下简称"公司"） 预计 2025 年年度实现归属于母公司所有者的净利润为人民币 4,000 万元到 4,800 万元，与上年同期（法定披露数据）相比，同比减少 62.23%至 68.52%。 （2）预计 2025 年度归属于母公司所有者的扣除非经常性损益后的净利润 为人民币 2,600 万元到 3,200 万元，与上年同期（法定披露数据）相比，同比减 少 68.23%至 74.19%。 二、上年同期业绩情况和财务状况 （一）公司 2024 年实现利润总额为 13,791.88 万元，归属于母公司所有者的 净利润为 12,707.47 万 ...

科美诊断公告，预计2025年年度实现的净利润为人民币4000万元到4800万元，同比减少62.23%至 68.52%。预计2025年度归属于母公司所有者的扣除非经常性损益后的净利润为人民币2600万元到3200 万元，与上年同期（法定披露数据）相比，同比减少68.23%至74.19%。公司2024年实现的净利润为1.27 亿元，归属于母公司所有者的扣除非经常性损益后的净利润为1.01亿元。 ...

Group 1 - The core point of the news is that Kemei Diagnostics experienced a stock price increase of 5.18%, reaching 7.72 CNY per share, with a total market capitalization of 3.097 billion CNY as of January 5 [1] - Kemei Diagnostics, established on May 10, 2007, and listed on April 9, 2021, specializes in the research, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments [1] - The main revenue composition of Kemei Diagnostics is derived from LiCA series products (93.42%) and CC series products (6.58%) [1] Group 2 - According to data, Penghua Fund has a significant holding in Kemei Diagnostics through its Penghua Quantitative Pioneer Mixed Fund (005632), which held 69,200 shares, accounting for 0.46% of the fund's net value [2] - The Penghua Quantitative Pioneer Mixed Fund has achieved a year-to-date return of 38.28%, ranking 2189 out of 8155 in its category [2] - The fund manager, Shi Yunchao, has been in charge for 1 year and 9 days, with the fund's total asset size at 2.59 billion CNY [3]

Group 1 - The core viewpoint of the news is that Kemei Diagnostics experienced a decline in stock price and trading volume, indicating potential market concerns about its financial performance and investor sentiment [1] - On November 21, Kemei Diagnostics' stock fell by 5.22%, with a trading volume of 53.33 million yuan. The net financing purchase on that day was 471,600 yuan, with a total financing and securities balance of 165 million yuan [1] - The financing balance of Kemei Diagnostics is 165 million yuan, accounting for 5.38% of its circulating market value, which is below the 30th percentile level over the past year, indicating a low financing level [1] Group 2 - As of September 30, Kemei Diagnostics had 10,400 shareholders, a decrease of 0.60% from the previous period, while the average circulating shares per person increased by 0.61% to 38,586 shares [2] - For the period from January to September 2025, Kemei Diagnostics reported operating revenue of 261 million yuan, a year-on-year decrease of 24.13%, and a net profit attributable to shareholders of 41.56 million yuan, down 62.94% year-on-year [2] - Kemei Diagnostics has distributed a total of 306 million yuan in dividends since its A-share listing, with 238 million yuan distributed over the past three years [3]

Core Viewpoint - Kemei Diagnostics, established in 2007 and listed in 2021, specializes in clinical immunochemistry and has unique technological advantages in the in vitro diagnostics sector [1] Group 1: Business Performance - In Q3 2025, Kemei Diagnostics reported revenue of 261 million yuan, ranking 25th in the industry, significantly lower than the top competitor's revenue of 3.428 billion yuan [2] - The main business revenue is primarily from LiCA series products, contributing 154 million yuan, accounting for 93.42% of total revenue [2] - The net profit for the same period was 41.56 million yuan, ranking 18th in the industry, but higher than the industry median of 26.19 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Kemei Diagnostics had a debt-to-asset ratio of 20.50%, which is higher than the industry average of 18.29% [3] - The gross profit margin for the same period was 68.02%, exceeding the industry average of 56.20% [3] Group 3: Executive Compensation - The chairman and general manager, Li Lin, received a salary of 962,200 yuan in 2024, a decrease of 399,400 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.60% to 10,400 [5] - The average number of circulating A-shares held per shareholder increased by 0.61% to 38,600 [5]

Financial Performance - Total revenue for Q3 2025 was ¥96,206,475.83, a decrease of 18.61% compared to the same period last year[3] - Net profit attributable to shareholders was ¥17,221,945.26, down 51.50% year-over-year[3] - The total profit for the year-to-date period decreased by 63.92% to ¥46,155,660.46[3] - Basic earnings per share for Q3 2025 was ¥0.04, a decline of 55.56% compared to the previous year[3] - The company's revenue for the reporting period was CNY 260.82 million, a year-on-year decrease of 24.13%[12] - Net profit attributable to shareholders was CNY 41.56 million, down 62.94% year-on-year[12] - Total operating revenue for the first three quarters of 2025 was CNY 260,821,861.59, a decrease of 24.1% compared to CNY 343,786,670.77 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was CNY 41,562,776.02, a decline of 63.0% compared to CNY 112,150,960.47 in the same period of 2024[20] - Operating profit for the first three quarters of 2025 was CNY 45,983,456.08, down 64.0% from CNY 128,141,009.06 in the previous year[20] Research and Development - R&D investment totaled ¥20,744,668.54, representing 21.56% of total revenue, an increase of 4.92 percentage points[4] - The company continues to invest in R&D, focusing on innovative products and technologies to meet clinical needs[12] - Research and development expenses increased to CNY 56,428,488.49 in 2025, up 15.0% from CNY 48,830,331.80 in 2024[20] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥71,178,778.38, down 47.41% year-over-year[3] - Cash and cash equivalents increased to CNY 648.39 million from CNY 400.25 million as of December 31, 2024[15] - Total current assets decreased to CNY 1,030.99 million from CNY 1,067.68 million[15] - The company's cash flow from operating activities for the first three quarters of 2025 showed a significant change, reflecting ongoing adjustments in operational efficiency[22] - Cash inflow from operating activities for the first three quarters of 2025 was $300.41 million, a decrease of 27% compared to $411.58 million in the same period of 2024[23] - Net cash flow from operating activities for the first three quarters of 2025 was $71.18 million, down 47.4% from $135.33 million in 2024[24] - Total assets at the end of the reporting period were ¥1,771,711,225.11, a decrease of 3.30% from the previous year-end[4] - The company's total assets decreased to CNY 1,771,711,225.11 in 2025 from CNY 1,832,158,296.89 in 2024, a reduction of 3.3%[17] Shareholder Information - The top shareholder, Ningbo Free Trade Zone Yingweili Enterprise Management, holds 26.93% of shares[10] - The company maintained a basic and diluted earnings per share of CNY 0.10 for the first three quarters of 2025, down from CNY 0.28 in the same period of 2024[21] Operational Strategy - The company aims to enhance its product pipeline through a dual strategy of import substitution and clinical interaction[12] - The company holds a leading position with its proprietary LICA® technology platform, emphasizing cost-effective clinical products[12] - The company has a robust strategy to address unmet clinical needs and high-burden disease areas[12] Inventory and Costs - The company has maintained a stable inventory level, with inventory reported at CNY 113.82 million[15] - Total operating costs for the first three quarters of 2025 were CNY 223,690,330.27, down from CNY 234,109,060.40 in the previous year, reflecting a reduction of 4.0%[19] Liabilities and Tax - Total liabilities decreased to CNY 363,165,455.02 in 2025 from CNY 415,851,159.52 in 2024, a decline of 12.6%[17] - The company reported cash outflows for tax payments of $31.77 million in 2025, a decrease from $60.59 million in 2024, representing a reduction of 47.5%[24]